Credit: Getty Images. A PDUFA target date of May 29, 2023 has been set for the application. The Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee unanimously voted 12-0 in ...
Hospital-acquired infections are often hard to treat because the corresponding pathogens become increasingly resistant against antibiotics. The bacterium Acinetobacter baumannii is particularly feared ...
A research team has discovered a fundamental mechanism that helps the dreaded hospital pathogen Acinetobacter baumannii to survive. This mechanism explains why the pathogen is difficult to eradicate ...
XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to carbapenems ...
Acinetobacter baumannii is a bacteria which can become a virulent killer in health-care settings among severely ill patients. The germ has rapidly developed drug resistance to even last-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results